Immuno-Oncology | Specialty

Improving Care in Locally Advanced NSCLC

March 13th 2018

Tips for Managing NSCLC Patients on Durvalumab Therapy

March 13th 2018

NSCLC: Consolidation Immunotherapy in Practice

March 13th 2018

Chemotherapy Choices in the PACIFIC Trial

March 13th 2018

PACIFIC Trial: A Game Changer in Unresectable LA NSCLC

March 13th 2018

Locally Advanced NSCLC: Treatment Overview

March 13th 2018

Key Considerations in the Management of Stage 3 NSCLC

March 13th 2018

Locally Advanced NSCLC: Treatment Goals and Challenges

March 13th 2018

New Paradigms for Treatment of Locally Advanced NSCLC

March 13th 2018

Dr. Gupta on the Role of Surgery in Bladder Cancer

March 12th 2018

Amit Gupta, MD, urologic oncologist, Department of Surgery, Cedars-Sinai Medical Center, discusses how the use of immunotherapy agents is altering the role of surgery in bladder cancer and the need for Bacillus Calmette-Guérin (BCG) alternatives.

Emerging Advances for Immunotherapy in Urothelial Cancer

March 9th 2018

Promise of DNA Vaccines in Bladder Cancer

March 9th 2018

Improving Responses to Immunotherapy in Bladder Cancer

March 9th 2018

Ongoing Immuno-Oncology Research in Bladder Cancer

March 9th 2018

A Therapeutic Revolution: Immunotherapy for Bladder Cancer

March 9th 2018

Dr. Andre on Questions With Immunotherapy in Triple-Negative Breast Cancer

March 9th 2018

Fabrice André, MD, professor, Department of Medical Oncology, Institut Gustave Roussy, discusses the remaining questions with immunotherapy agents as potential therapy for patients with triple-negative breast cancer. Andre expanded on this in an interview with OncLive during the 35th Annual Miami Breast Cancer Conference.

Figlin Discusses Optimizing Expanding Treatment Options in RCC

March 8th 2018

Robert A. Figlin, MD, discusses the expanding RCC armamentarium and balancing the benefits and risks of standard and emerging treatments to achieve optimal outcomes.

Dr. Weber on the FDA Approval for Fixed-Dose of Nivolumab

March 6th 2018

Jeffrey S. Weber, MD, PhD, deputy director and co-director of the Melanoma Program at the Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center, 2016 Giant of Cancer Care

FDA Approves 4-Week Nivolumab Dosing Schedule

March 6th 2018

The FDA has approved a supplemental biologics license application adding a 4-week dosing schedule for nivolumab across several of the PD-1 inhibitor’s indications.

Optimal Sequencing Key to Capitalizing on RCC Advances

March 6th 2018

Thai H. Ho, MD, PhD, discusses treatment advances in first-line RCC and how biomarker development and optimal sequencing are critical next steps to building on recent breakthroughs.